Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
about
Recent advances of novel targeted therapy in non-small cell lung cancerThird-line systemic treatment for non-small cell lung cancerTaxane schedules for non-small cell lung cancerTaxane schedules for non-small cell lung cancerReinforcement learning design for cancer clinical trialsOptimizing the management of advanced non-small-cell lung cancer: a personal viewClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerThe Evolution of Therapies in Non-Small Cell Lung CancerMedical management of lung cancer: Experience in ChinaDiscovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapySecond-Line Therapy for Advanced NSCLCMaintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old ideaLung cancer vaccines50 Years of progress in the systemic therapy of non-small cell lung cancerUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewRole of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumorsAccelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacyEstablishment of a first‑line second‑line treatment model for human pulmonary adenocarcinomaNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerReal-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung CancerMulticenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial dataCost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma.Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
P2860
Q21092930-BD0C4C95-7EE2-4291-A831-B72CCD354B66Q24194090-610C6467-64ED-4BC8-B852-2F024B988C40Q24200956-A51E86B7-0B71-4FFF-96B6-0FC09AA8B2E2Q24241210-BF726343-050D-4B0D-AA5A-E1E1553492E9Q24648505-A4D316BF-26D2-46D2-B722-B022CE2D5C99Q24656144-FA986F71-C6FF-4DB3-86A2-89AB42266188Q24678961-C20D986F-5BD6-451E-9BB1-3F8EB4BBF8B6Q26745590-301D4FF8-E22F-463F-8482-405DF52701C7Q26786932-77AC1237-CD7C-44FF-832D-93CE2691E559Q26798257-B51E0193-5101-4EBB-9356-A922E5A126ACQ26801584-969E4CD0-09D7-4CAC-974C-F9D6E68312A8Q27002398-320A39AE-B847-4380-A98F-8A0EAA5FF527Q27011282-1AEA9886-33A0-4B7B-A39B-269EEC3BA7AAQ27014375-7B43E772-4AAB-4F52-A08C-7A65E3545117Q27014978-57E3C33C-9DA0-473E-8CBC-99FB84BF8BF5Q27022535-7B97444E-17CD-4226-BE36-006D574152B9Q27025724-4D1C3E77-9E5C-48FE-99A4-70A81C6F2C63Q27853199-15830E55-C242-4D7E-903F-013E429557E0Q28068643-50967488-8262-4D71-82CA-40D6AC4794A7Q28081243-351F8108-EA79-4B2E-A4DD-490647E769BBQ28292264-9EAC7F61-5276-445B-A8E6-EE58A3C0B3AAQ28364868-AC70D330-45B1-41F3-BCBB-8DE379659D53Q28468342-472C6BD5-7649-4B06-9B3C-0F8EE9F9C7BAQ29620902-E9E6C76A-964D-45AF-810C-DBA022FCDD5EQ29620913-FDDDF7DB-8636-41DB-90E8-33A4B374B433Q30234800-640F867A-E3E9-4CB6-8015-65BE88C39339Q30317149-A55EC0B0-5D74-48DB-BF45-D1DAD1B52E9AQ30422736-6818A640-28E7-4706-A5F4-35DCBD26D2F8Q30940337-66CC1266-66D7-4220-9997-B974BF022A7FQ30977332-FAFEDAC1-4157-4FE1-A1BB-2890B0A994E1Q30978996-1A867848-0E61-4FF8-AA48-FE97A893A783Q33159653-D8E16887-E622-4FEE-946C-7C1249CCD1D4Q33248481-E6D4CFDB-7F9B-40F4-A785-DC72188B3DC5Q33338040-080DC9AD-E10A-41D7-8A3F-CEFBEF061DC8Q33340278-DABCFE16-D6C7-4F53-A3B7-133DBC8A12E9Q33341156-3DC802A4-5A9B-43C7-BA6E-DC57F41B1222Q33341208-0D757838-B2BB-4C26-B4D0-930B150D5CD9Q33343275-B7651DD9-B805-4FCC-8F72-37CB6077E9A1Q33344133-6F20909A-2360-4FD7-8971-49B7ED5C7C55Q33346376-E8A568BB-3B2B-4DDE-9470-3213C263BB63
P2860
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Prospective randomized trial o ...... h platinum-based chemotherapy.
@en
Prospective randomized trial o ...... h platinum-based chemotherapy.
@nl
type
label
Prospective randomized trial o ...... h platinum-based chemotherapy.
@en
Prospective randomized trial o ...... h platinum-based chemotherapy.
@nl
prefLabel
Prospective randomized trial o ...... h platinum-based chemotherapy.
@en
Prospective randomized trial o ...... h platinum-based chemotherapy.
@nl
P2093
P1476
Prospective randomized trial o ...... h platinum-based chemotherapy.
@en
P2093
F A Shepherd
M O'Rourke
P304
P356
10.1200/JCO.2000.18.10.2095
P407
P577
2000-05-01T00:00:00Z